Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In

This article was originally published in The Pink Sheet Daily

Executive Summary

Partners will start an all-new BiTE project and continue working on another, while Micromet takes over worldwide development of blinatumomab, for which MedImmune retains a commercialization option.

You may also be interested in...



Micromet Reacquires Full North American Rights To Blinatumomab

Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.

Micromet Reacquires Full North American Rights To Blinatumomab

Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.

Taking a BiTE Out of Cancer: An Interview With Micromet CEO Christian Itin

After securing $80.5 million in financing in August and renegotiating a partnership with MedImmune, Micromet is on course to take its first BiTE antibody into pivotal trials in 2010.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel